Great presentation Tom Duthy, well done! I'm surprised to...

Great presentation Tom Duthy, well done!

I'm surprised to see negativity in these forums when I look at the fundamentals and the developments the last 12 months, I as an investor am happy with the progress and understand that they have navigated the regulatory bodies as well as I could have hoped - some companies get stuck in FDA talks for years. Just the nature of biotechs to have periods of multiple years inbetween phases where admin work is being done behind the scenes.

To get this moving with the majority of TAM accessible via this trial for EU/UK/AU, to get the enrolment newsflow coming during the next 6-9 months, people will realise how low this phase 3 really is valued at and align it with the evident upside in an unencumbered market in the scenario that phase 3 is a success. FDA can wait until after EU/UK/AU, if it means higher asymmetry in our positions as shareholders to maximise our value. That's good management.

This is a LT hold, should only invest what you're willing to forgo in opportunity cost, but with catalysts on the horizon and at this low of basement levels, the possible multiples are undeniable.

Not financial advice.